Genitourinary dysfunction in Parkinson's disease
Identifieur interne : 000C48 ( Istex/Corpus ); précédent : 000C47; suivant : 000C49Genitourinary dysfunction in Parkinson's disease
Auteurs : Ryuji Sakakibara ; Tomoyuki Uchiyama ; Tomonori Yamanishi ; Masahiko KishiSource :
- Movement Disorders [ 0885-3185 ] ; 2010-01-15.
English descriptors
- KwdEn :
Abstract
Bladder dysfunction (urinary urgency/frequency) and sexual dysfunction (erectile dysfunction) are common nonmotor disorders in Parkinson's disease (PD). In contrast to motor disorders, genitourinary autonomic dysfunctions are often nonresponsive to levodopa treatment. The brain pathology causing the bladder dysfunction (appearance of overactivity) involves an altered dopamine‐basal ganglia circuit, which normally suppresses the micturition reflex. By contrast, hypothalamic dysfunction is mostly responsible for the sexual dysfunction (decrease in libido and erection) in PD, via altered dopamine‐oxytocin pathways, which normally promote libido and erection. The pathophysiology of the genitourinary dysfunction in PD differs from that in multiple system atrophy; therefore, it might aid in differential diagnosis. Anticholinergic agents are used to treat bladder dysfunction in PD, although these drugs should be used with caution particularly in elderly patients who have cognitive decline. Phosphodiesterase inhibitors are used to treat sexual dysfunction in PD. These treatments might be beneficial in maximizing the patients' quality of life. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22519
Links to Exploration step
ISTEX:2522D61E7D3D87A8EA987AA52B3D96C2E1E2DA73Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Genitourinary dysfunction in Parkinson's disease</title><author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name><affiliation><mods:affiliation>Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, Shimoshizu, Sakura, Japan</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, Chiba University, Chiba, Japan</mods:affiliation></affiliation></author><author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name><affiliation><mods:affiliation>Department of Neurology, Chiba University, Chiba, Japan</mods:affiliation></affiliation></author><author><name sortKey="Yamanishi, Tomonori" sort="Yamanishi, Tomonori" uniqKey="Yamanishi T" first="Tomonori" last="Yamanishi">Tomonori Yamanishi</name><affiliation><mods:affiliation>Department of Urology, Dokkyo Medical College, Tochigi, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kishi, Masahiko" sort="Kishi, Masahiko" uniqKey="Kishi M" first="Masahiko" last="Kishi">Masahiko Kishi</name><affiliation><mods:affiliation>Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, Shimoshizu, Sakura, Japan</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2522D61E7D3D87A8EA987AA52B3D96C2E1E2DA73</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22519</idno><idno type="url">https://api.istex.fr/document/2522D61E7D3D87A8EA987AA52B3D96C2E1E2DA73/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000C48</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Genitourinary dysfunction in Parkinson's disease</title><author><name sortKey="Sakakibara, Ryuji" sort="Sakakibara, Ryuji" uniqKey="Sakakibara R" first="Ryuji" last="Sakakibara">Ryuji Sakakibara</name><affiliation><mods:affiliation>Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, Shimoshizu, Sakura, Japan</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, Chiba University, Chiba, Japan</mods:affiliation></affiliation></author><author><name sortKey="Uchiyama, Tomoyuki" sort="Uchiyama, Tomoyuki" uniqKey="Uchiyama T" first="Tomoyuki" last="Uchiyama">Tomoyuki Uchiyama</name><affiliation><mods:affiliation>Department of Neurology, Chiba University, Chiba, Japan</mods:affiliation></affiliation></author><author><name sortKey="Yamanishi, Tomonori" sort="Yamanishi, Tomonori" uniqKey="Yamanishi T" first="Tomonori" last="Yamanishi">Tomonori Yamanishi</name><affiliation><mods:affiliation>Department of Urology, Dokkyo Medical College, Tochigi, Japan</mods:affiliation></affiliation></author><author><name sortKey="Kishi, Masahiko" sort="Kishi, Masahiko" uniqKey="Kishi M" first="Masahiko" last="Kishi">Masahiko Kishi</name><affiliation><mods:affiliation>Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, Shimoshizu, Sakura, Japan</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-01-15">2010-01-15</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="2">2</biblScope><biblScope unit="page" to="12">12</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">2522D61E7D3D87A8EA987AA52B3D96C2E1E2DA73</idno><idno type="DOI">10.1002/mds.22519</idno><idno type="ArticleID">MDS22519</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>autonomic nervous system</term><term>bladder dysfunction</term><term>dopamine</term><term>sexual dysfunction</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Bladder dysfunction (urinary urgency/frequency) and sexual dysfunction (erectile dysfunction) are common nonmotor disorders in Parkinson's disease (PD). In contrast to motor disorders, genitourinary autonomic dysfunctions are often nonresponsive to levodopa treatment. The brain pathology causing the bladder dysfunction (appearance of overactivity) involves an altered dopamine‐basal ganglia circuit, which normally suppresses the micturition reflex. By contrast, hypothalamic dysfunction is mostly responsible for the sexual dysfunction (decrease in libido and erection) in PD, via altered dopamine‐oxytocin pathways, which normally promote libido and erection. The pathophysiology of the genitourinary dysfunction in PD differs from that in multiple system atrophy; therefore, it might aid in differential diagnosis. Anticholinergic agents are used to treat bladder dysfunction in PD, although these drugs should be used with caution particularly in elderly patients who have cognitive decline. Phosphodiesterase inhibitors are used to treat sexual dysfunction in PD. These treatments might be beneficial in maximizing the patients' quality of life. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Ryuji Sakakibara MD, PhD</name><affiliations><json:string>Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, Shimoshizu, Sakura, Japan</json:string><json:string>Department of Neurology, Chiba University, Chiba, Japan</json:string></affiliations></json:item><json:item><name>Tomoyuki Uchiyama MD, PhD</name><affiliations><json:string>Department of Neurology, Chiba University, Chiba, Japan</json:string></affiliations></json:item><json:item><name>Tomonori Yamanishi MD</name><affiliations><json:string>Department of Urology, Dokkyo Medical College, Tochigi, Japan</json:string></affiliations></json:item><json:item><name>Masahiko Kishi</name><affiliations><json:string>Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, Shimoshizu, Sakura, Japan</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>bladder dysfunction</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>sexual dysfunction</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>autonomic nervous system</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Bladder dysfunction (urinary urgency/frequency) and sexual dysfunction (erectile dysfunction) are common nonmotor disorders in Parkinson's disease (PD). In contrast to motor disorders, genitourinary autonomic dysfunctions are often nonresponsive to levodopa treatment. The brain pathology causing the bladder dysfunction (appearance of overactivity) involves an altered dopamine‐basal ganglia circuit, which normally suppresses the micturition reflex. By contrast, hypothalamic dysfunction is mostly responsible for the sexual dysfunction (decrease in libido and erection) in PD, via altered dopamine‐oxytocin pathways, which normally promote libido and erection. The pathophysiology of the genitourinary dysfunction in PD differs from that in multiple system atrophy; therefore, it might aid in differential diagnosis. Anticholinergic agents are used to treat bladder dysfunction in PD, although these drugs should be used with caution particularly in elderly patients who have cognitive decline. Phosphodiesterase inhibitors are used to treat sexual dysfunction in PD. These treatments might be beneficial in maximizing the patients' quality of life. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>6.872</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1185</abstractCharCount><pdfWordCount>6956</pdfWordCount><pdfCharCount>47105</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>156</abstractWordCount></qualityIndicators><title>Genitourinary dysfunction in Parkinson's disease</title><genre><json:string>Serial article</json:string></genre><host><volume>25</volume><pages><total>11</total><last>12</last><first>2</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Review</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.22519</json:string></doi><id>2522D61E7D3D87A8EA987AA52B3D96C2E1E2DA73</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/2522D61E7D3D87A8EA987AA52B3D96C2E1E2DA73/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/2522D61E7D3D87A8EA987AA52B3D96C2E1E2DA73/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/2522D61E7D3D87A8EA987AA52B3D96C2E1E2DA73/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Genitourinary dysfunction in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Nothing to report.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Genitourinary dysfunction in Parkinson's disease</title><author><persName><forename type="first">Ryuji</forename><surname>Sakakibara</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, 564‐1 Shimoshizu, Sakura, 285‐8741 Japan</p></note><affiliation>Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, Shimoshizu, Sakura, Japan</affiliation><affiliation>Department of Neurology, Chiba University, Chiba, Japan</affiliation></author><author><persName><forename type="first">Tomoyuki</forename><surname>Uchiyama</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Neurology, Chiba University, Chiba, Japan</affiliation></author><author><persName><forename type="first">Tomonori</forename><surname>Yamanishi</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Urology, Dokkyo Medical College, Tochigi, Japan</affiliation></author><author><persName><forename type="first">Masahiko</forename><surname>Kishi</surname></persName><affiliation>Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, Shimoshizu, Sakura, Japan</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-01-15"></date><biblScope unit="vol">25</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="2">2</biblScope><biblScope unit="page" to="12">12</biblScope></imprint></monogr><idno type="istex">2522D61E7D3D87A8EA987AA52B3D96C2E1E2DA73</idno><idno type="DOI">10.1002/mds.22519</idno><idno type="ArticleID">MDS22519</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Bladder dysfunction (urinary urgency/frequency) and sexual dysfunction (erectile dysfunction) are common nonmotor disorders in Parkinson's disease (PD). In contrast to motor disorders, genitourinary autonomic dysfunctions are often nonresponsive to levodopa treatment. The brain pathology causing the bladder dysfunction (appearance of overactivity) involves an altered dopamine‐basal ganglia circuit, which normally suppresses the micturition reflex. By contrast, hypothalamic dysfunction is mostly responsible for the sexual dysfunction (decrease in libido and erection) in PD, via altered dopamine‐oxytocin pathways, which normally promote libido and erection. The pathophysiology of the genitourinary dysfunction in PD differs from that in multiple system atrophy; therefore, it might aid in differential diagnosis. Anticholinergic agents are used to treat bladder dysfunction in PD, although these drugs should be used with caution particularly in elderly patients who have cognitive decline. Phosphodiesterase inhibitors are used to treat sexual dysfunction in PD. These treatments might be beneficial in maximizing the patients' quality of life. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>bladder dysfunction</term></item><item><term>sexual dysfunction</term></item><item><term>autonomic nervous system</term></item><item><term>dopamine</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-05-09">Received</change><change when="2009-01-28">Registration</change><change when="2010-01-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/2522D61E7D3D87A8EA987AA52B3D96C2E1E2DA73/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v25:1</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2010-01-15">15 January 2010</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="2" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22519</doi><idGroup><id type="unit" value="MDS22519"></id></idGroup><countGroup><count type="pageTotal" number="11"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-05-09"></event><event type="manuscriptRevised" date="2009-01-27"></event><event type="manuscriptAccepted" date="2009-01-28"></event><event type="firstOnline" date="2010-01-13"></event><event type="publishedOnlineFinalForm" date="2010-01-25"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-01-13"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.1.9 mode:FullText" date="2013-01-28"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2</numbering><numbering type="pageLast">12</numbering></numberingGroup><correspondenceTo>Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, 564‐1 Shimoshizu, Sakura, 285‐8741 Japan</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22519.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="4"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="132"></count><count type="wordTotal" number="6977"></count></countGroup><titleGroup><title type="main" xml:lang="en">Genitourinary dysfunction in Parkinson's disease<link href="#fn1"></link></title><title type="short" xml:lang="en">Genitourinary Dysfunction</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Ryuji</givenNames><familyName>Sakakibara</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email normalForm="sakakibara@sakura.med.toho-u.ac.jp">sakakibara@sakura.med.toho‐u.ac.jp</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Tomoyuki</givenNames><familyName>Uchiyama</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Tomonori</givenNames><familyName>Yamanishi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Masahiko</givenNames><familyName>Kishi</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="JP" type="organization"><unparsedAffiliation>Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, Shimoshizu, Sakura, Japan</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="JP" type="organization"><unparsedAffiliation>Department of Neurology, Chiba University, Chiba, Japan</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="JP" type="organization"><unparsedAffiliation>Department of Urology, Dokkyo Medical College, Tochigi, Japan</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">bladder dysfunction</keyword><keyword xml:id="kwd3">sexual dysfunction</keyword><keyword xml:id="kwd4">autonomic nervous system</keyword><keyword xml:id="kwd5">dopamine</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Bladder dysfunction (urinary urgency/frequency) and sexual dysfunction (erectile dysfunction) are common nonmotor disorders in Parkinson's disease (PD). In contrast to motor disorders, genitourinary autonomic dysfunctions are often nonresponsive to levodopa treatment. The brain pathology causing the bladder dysfunction (appearance of overactivity) involves an altered dopamine‐basal ganglia circuit, which normally suppresses the micturition reflex. By contrast, hypothalamic dysfunction is mostly responsible for the sexual dysfunction (decrease in libido and erection) in PD, via altered dopamine‐oxytocin pathways, which normally promote libido and erection. The pathophysiology of the genitourinary dysfunction in PD differs from that in multiple system atrophy; therefore, it might aid in differential diagnosis. Anticholinergic agents are used to treat bladder dysfunction in PD, although these drugs should be used with caution particularly in elderly patients who have cognitive decline. Phosphodiesterase inhibitors are used to treat sexual dysfunction in PD. These treatments might be beneficial in maximizing the patients' quality of life. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: Nothing to report.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Genitourinary dysfunction in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Genitourinary Dysfunction</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Genitourinary dysfunction in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Ryuji</namePart><namePart type="family">Sakakibara</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, Shimoshizu, Sakura, Japan</affiliation><affiliation>Department of Neurology, Chiba University, Chiba, Japan</affiliation><description>Correspondence: Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, 564‐1 Shimoshizu, Sakura, 285‐8741 Japan</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tomoyuki</namePart><namePart type="family">Uchiyama</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Chiba University, Chiba, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tomonori</namePart><namePart type="family">Yamanishi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Urology, Dokkyo Medical College, Tochigi, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Masahiko</namePart><namePart type="family">Kishi</namePart><affiliation>Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, Shimoshizu, Sakura, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">reviewArticle</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-01-15</dateIssued><dateCaptured encoding="w3cdtf">2008-05-09</dateCaptured><dateValid encoding="w3cdtf">2009-01-28</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">4</extent><extent unit="references">132</extent><extent unit="words">6977</extent></physicalDescription><abstract lang="en">Bladder dysfunction (urinary urgency/frequency) and sexual dysfunction (erectile dysfunction) are common nonmotor disorders in Parkinson's disease (PD). In contrast to motor disorders, genitourinary autonomic dysfunctions are often nonresponsive to levodopa treatment. The brain pathology causing the bladder dysfunction (appearance of overactivity) involves an altered dopamine‐basal ganglia circuit, which normally suppresses the micturition reflex. By contrast, hypothalamic dysfunction is mostly responsible for the sexual dysfunction (decrease in libido and erection) in PD, via altered dopamine‐oxytocin pathways, which normally promote libido and erection. The pathophysiology of the genitourinary dysfunction in PD differs from that in multiple system atrophy; therefore, it might aid in differential diagnosis. Anticholinergic agents are used to treat bladder dysfunction in PD, although these drugs should be used with caution particularly in elderly patients who have cognitive decline. Phosphodiesterase inhibitors are used to treat sexual dysfunction in PD. These treatments might be beneficial in maximizing the patients' quality of life. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: Nothing to report.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>bladder dysfunction</topic><topic>sexual dysfunction</topic><topic>autonomic nervous system</topic><topic>dopamine</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Review</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>2</start><end>12</end><total>11</total></extent></part></relatedItem><identifier type="istex">2522D61E7D3D87A8EA987AA52B3D96C2E1E2DA73</identifier><identifier type="DOI">10.1002/mds.22519</identifier><identifier type="ArticleID">MDS22519</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000C48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:2522D61E7D3D87A8EA987AA52B3D96C2E1E2DA73
|texte= Genitourinary dysfunction in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |